Auzone Biological Technology (HK) Limited

Auzone’s flagship asset, TTYP01, is the world’s first and only oral Edaravone tablet. As the only neuroprotective agent with comprehensive evidence-based medical validation, Edaravone has long been widely recognized for its neurological protective efficacy. The newly developed oral formulation of TTYP01 achieves nearly 20-fold higher bioavailability compared with conventional formulations, greatly improving dosing convenience and patient treatment compliance. It enables the extensive clinical application of Edaravone in acute and chronic neurological diseases associated with oxidative stress, filling a 20-year market gap since the launch of Edaravone with no available oral dosage form. This groundbreaking innovation is poised to address significant unmet clinical needs in the global CNS treatment landscape.